Protection against hepatitis B by the Butang® recombinant vaccine in newborn children in South Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 101, Issue 5, 2006, Pages 551-553

  Isolani, Aline Paula ^a   Sversuti, Catia Silene ^a   Sell, Ana Maria ^a   Moliterno, Ricardo Alberto ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Anti HBsAg; Butang ; Hepatitis B; Vaccine

Indexed keywords

EID: 33747867789     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762006000500012     Document Type: Article

References (15)

1. Baldy JLS, Lima GZ, Morimoto K, Reiche EMV, Matsuo T, Mattos ED, Pulga LC 2004. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination. Rev Inst Med Trop São Paulo 46: 103-107.
2. Blumberg BS 1997. Hepatites B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sci USA 94: 7121-7125.
3. Costa AA, Inenami M, Juarez E, Llacen PD, Raw I 1997. Preliminary reporto f the use on adults of a recombinant yeast-derived hepatites B vaccine manufactured by Instituto Butantan. Rev Inst Med Trop São Paulo 39 :39-42.
4. Granovski N 1997. Recombinant hepatitis B vaccine: the usage of east Saccharomyces cerevisae expression system. Rev Farm Bioq Univ S Paulo 32: 61-70.
5. Hieu NT, Kim KH, Janowicz Z, Timmermans I 2002. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HbsAg and HbeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 20: 1803-1808.
6. Ioshimoto LM, Rissato ML, Bonilha VSJ, Miyaki C, Raw I, Granovski N 1999. Safety and immunogenecity of hepatitis B vaccine Butang in adults. Rev Inst Med Trop São Paulo 41: 191-193.
7. Losonsky GA, Wasserman SS, Stephens I, Mahoney F, Armstrong P, Gumpper K, Dulkerian S, West DJ, Gewold IH 1999. Hepatitis B vaccination of premature infants: a reassessment of current recommendation for delayed immunization. Pediatrics 103: 1-7.
8. Martins RM, Bensabath G, Arraes LC, Oliveira MLA, Miguel JC, Barbosa GG, Camacho LAB 2004. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz 99: 865-871.
9. Ministério da Saúde 2003. Secretaria de Políticas de Saúde. Programa Nacional de Hepatites Virais. O Brasil está atento. Brasília.
10. Moradpour D, Wands JR. 1995. Understanding hepatitis B virus infection. N Engl J Med 332: 1092-1093.
11. Motta MSM, Mussi-Pinhata MM, Jorge SM, Yoshida CFT, Souza CBS 2002. Immunogenicity of hepatites B in preterm and full term infants vaccinated within the first week of life. Vaccine 20: 1557-1562.
12. Sadeck LSR, Ramos JLA 2004. Immune response of preterm infants to hepatites B vaccine administred within 24 hours after birth. J Pediatr 80: 113-118.
13. SAS Institute Inc. 1989. SAS/STAT User's Guide, version 6, 4th ed., v.1, Cary.
14. West DJ, Calandra GB 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14: 1019-1027.
15. WHO-World Health Organization 2005. Hepatitis B. available in: http://www.who.int/mediacentre/ factsheets/fs204/en/. Access in: 26 of April, 2005.